CeriBell (NASDAQ:CBLL) Posts Quarterly Earnings Results, Misses Expectations By $0.04 EPS

CeriBell (NASDAQ:CBLL) released its quarterly earnings data on Monday. The company reported ($0.51) EPS for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.04), FiscalAI reports. CeriBell had a negative return on equity of 43.02% and a negative net margin of 64.73%.The firm had revenue of $28.10 million for the quarter, compared to analyst estimates of $27.28 million.

Here are the key takeaways from CeriBell’s conference call:

• Q2 revenue rose 33% year over year to $28.1 million, accelerating from 29% growth in Q1, while the active account base increased by 32 to 712. Management cited strong same-store utilization and expects 2026 revenue of $114 million-$117 million, up from prior guidance of $112 million-$116 million.
• Gross margin reached a record 92%, helped by a $1.6 million tariff refund; excluding the refund, margin was still 89%. Ceribell expects margins to remain in the high-80% range, supported by supply-chain savings and expanded manufacturing in Vietnam.
• Ceribell plans to commercially launch its Delirium monitoring solution in Q4 2026 after favorable pilot feedback and CMS approval of an NTAP providing up to $2,171 in incremental reimbursement per qualified patient. Neonatal and pediatric products also received early purchase orders, although management expects these newer offerings to contribute more meaningfully in 2027.
• Operating expenses increased 37% year over year to $45.9 million, contributing to a net loss of $19.3 million, or $0.51 per share. The company continues to reinvest heavily in sales, R&D and platform development, and has not yet specified when it will achieve cash-flow breakeven.
• The company received FDA clearances for artifact-reduction and epileptiform-abnormality algorithms, as well as components of a next-generation hardware platform designed for video, ECG, longer-duration monitoring and full-montage EEG. Limited releases are planned before a broader 2027 launch, which management views as a potential expansion into additional patient populations and markets.

CeriBell Stock Up 10.4%

Shares of CeriBell stock opened at $21.31 on Wednesday. CeriBell has a 1-year low of $10.85 and a 1-year high of $24.33. The company has a market capitalization of $808.50 million, a PE ratio of -12.11 and a beta of 0.81. The company has a debt-to-equity ratio of 0.14, a current ratio of 10.44 and a quick ratio of 10.01. The business has a 50-day moving average of $18.63 and a 200-day moving average of $19.07.

Insider Transactions at CeriBell

In other CeriBell news, CTO Raymond Woo sold 1,966 shares of the firm’s stock in a transaction that occurred on Thursday, May 21st. The stock was sold at an average price of $18.00, for a total transaction of $35,388.00. Following the completion of the sale, the chief technology officer owned 195,682 shares in the company, valued at $3,522,276. This trade represents a 0.99% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director William W. Burke sold 2,207 shares of the company’s stock in a transaction that occurred on Tuesday, June 30th. The shares were sold at an average price of $19.84, for a total value of $43,786.88. Following the completion of the transaction, the director directly owned 23,022 shares in the company, valued at approximately $456,756.48. The trade was a 8.75% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 300,685 shares of company stock valued at $5,935,326 in the last three months. 17.70% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. nVerses Capital LLC acquired a new stake in shares of CeriBell during the 4th quarter valued at approximately $282,000. Engineers Gate Manager LP acquired a new position in CeriBell in the fourth quarter worth $260,000. Price T Rowe Associates Inc. MD boosted its holdings in CeriBell by 15.4% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 15,051 shares of the company’s stock worth $331,000 after purchasing an additional 2,008 shares during the period. Royal Bank of Canada increased its stake in CeriBell by 10.8% during the fourth quarter. Royal Bank of Canada now owns 15,588 shares of the company’s stock valued at $342,000 after purchasing an additional 1,514 shares during the last quarter. Finally, Verition Fund Management LLC acquired a new stake in shares of CeriBell during the fourth quarter worth $261,000.

Analysts Set New Price Targets

A number of equities analysts have recently commented on CBLL shares. Canaccord Genuity Group raised their price objective on CeriBell from $25.00 to $26.00 and gave the stock a “buy” rating in a report on Tuesday. BTIG Research reiterated a “buy” rating and set a $28.00 price objective on shares of CeriBell in a research note on Tuesday. Finally, Weiss Ratings downgraded shares of CeriBell from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, July 14th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $22.00.

About CeriBell

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.